A three-judge panel has reversed a $7 million judgment against the maker of the acne drug Accutane.
The 1st District Court of Appeal panel ruled in favor of Hoffman-La Roche Inc. and against a Pensacola man who had most of his colon removed due to Crohn’s disease linked to Accutane.
The unanimous opinion said the patient, Adam Mason, failed to prove an allegedly deficient warning label was the proximate cause of his ailment.
Mason had argued warning that Accutane was “temporally associated” with inflammatory bowel disease was too weak.
But his dermatologist testified he would have prescribed the drug even if the warning had been stronger.
Copyright 2025 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Was this article valuable?
Here are more articles you may enjoy.
Standard Chartered Settles $2 Billion Iranian Sanction Suit in London
‘Super Roofs’ Are Rewarding Insurers, Cat Bond Investors and Homeowners
UPS, FedEx Scramble to Shore Up Networks Drained by Deadly Crash
Hong Kong Orders Citywide Scaffolding Nets Removal After Blaze